The Microbial Diversity Following Antibiotic Treatment of Clostridioides Difficile Infection

Overview

Journal BMC Gastroenterol

Publisher Biomed Central

Specialty Gastroenterology

Date 2021 Apr 14

PMID 33849457

Citations 8

Authors

Dana Binyamin

Orna Nitzan

Maya Azrad

Zohar Hamo

Omry Koren

Avi Peretz

Affiliations

Soon will be listed here.

Abstract

Background: Clostridioides difficile (C. difficile) is a major nosocomial pathogen that infects the human gut and can cause diarrheal disease. A dominant risk factor is antibiotic treatment that disrupts the normal gut microbiota. The aim of the study was to examine the correlation between antibiotic treatment received prior to C. difficile infection (CDI) onset and patient gut microbiota.

Methods: Stool samples were collected from patients with CDI, presenting at the Baruch Padeh Medical Center Poriya, Israel. Demographic and clinical information, including previous antibiotic treatments, was collected from patient charts, and CDI severity score was calculated. Bacteria were isolated from stool samples, and gut microbiome was analyzed by sequencing the 16S rRNA gene using the Illumina MiSeq platform and QIIME2.

Results: In total, 84 patients with CDI were enrolled in the study; all had received antibiotics prior to disease onset. Due to comorbidities, 46 patients (55%) had received more than one class of antibiotics. The most common class of antibiotics used was cephalosporins (n = 44 cases). The intestinal microbiota of the patients was not uniform and was mainly dominated by Proteobacteria. Differences in intestinal microbiome were influenced by the different combinations of antibiotics that the patients had received (p = 0.022) CONCLUSIONS: The number of different antibiotics administered has a major impact on the CDI patients gut microbiome, mainly on bacterial richness.

Citing Articles

Can Gut Microbiota Analysis Reveal Infection? Evidence from an Italian Cohort at Disease Onset.

Rosato R, Quaranta G, Santarelli G, Fancello G, Bianco D, Monzo F Microorganisms. 2025; 13(1).

PMID: 39858784 PMC: 11767363. DOI: 10.3390/microorganisms13010016.

Antibiotic-perturbed microbiota and the role of probiotics.

Szajewska H, Scott K, de Meij T, Forslund-Startceva S, Knight R, Koren O Nat Rev Gastroenterol Hepatol. 2024; 22(3):155-172.

PMID: 39663462 DOI: 10.1038/s41575-024-01023-x.

Insights into Gut Dysbiosis: Inflammatory Diseases, Obesity, and Restoration Approaches.

Acevedo-Roman A, Pagan-Zayas N, Velazquez-Rivera L, Torres-Ventura A, Godoy-Vitorino F Int J Mol Sci. 2024; 25(17).

PMID: 39273662 PMC: 11396321. DOI: 10.3390/ijms25179715.

Children with idiopathic short stature have significantly different gut microbiota than their normal height siblings: a case-control study.

Lazar L, Eshel A, Moadi L, Yackobovitch-Gavan M, Bar-Maisels M, Shtaif B Front Endocrinol (Lausanne). 2024; 15:1343337.

PMID: 38464968 PMC: 10920232. DOI: 10.3389/fendo.2024.1343337.

Multi-omics analysis of hospital-acquired diarrhoeal patients reveals biomarkers of enterococcal proliferation and Clostridioides difficile infection.

Bosnjak M, Karpe A, Van T, Kotsanas D, Jenkin G, Costello S Nat Commun. 2023; 14(1):7737.

PMID: 38007555 PMC: 10676382. DOI: 10.1038/s41467-023-43671-8.

References

. Structure, function and diversity of the healthy human microbiome. Nature. 2012; 486(7402):207-14. PMC: 3564958. DOI: 10.1038/nature11234. View

Callahan B, McMurdie P, Rosen M, Han A, Johnson A, Holmes S . DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods. 2016; 13(7):581-3. PMC: 4927377. DOI: 10.1038/nmeth.3869. View

Pakpour S, Bhanvadia A, Zhu R, Amarnani A, Gibbons S, Gurry T . Identifying predictive features of Clostridium difficile infection recurrence before, during, and after primary antibiotic treatment. Microbiome. 2017; 5(1):148. PMC: 5684761. DOI: 10.1186/s40168-017-0368-1. View

Sangster W, Hegarty J, Schieffer K, Wright J, Hackman J, Toole D . Bacterial and Fungal Microbiota Changes Distinguish C. difficile Infection from Other Forms of Diarrhea: Results of a Prospective Inpatient Study. Front Microbiol. 2016; 7:789. PMC: 4879479. DOI: 10.3389/fmicb.2016.00789. View

Santos S, Nielsen T, Hansen L, Winding A . Comparison of three DNA extraction methods for recovery of soil protist DNA. J Microbiol Methods. 2015; 115:13-9. DOI: 10.1016/j.mimet.2015.05.011. View

Hogenauer C, Hammer H, Krejs G, Reisinger E . Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis. 1998; 27(4):702-10. DOI: 10.1086/514958. View

Clabots C, Johnson S, Olson M, Peterson L, Gerding D . Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis. 1992; 166(3):561-7. DOI: 10.1093/infdis/166.3.561. View

Warriner K, Xu C, Habash M, Sultan S, Weese S . Dissemination of Clostridium difficile in food and the environment: Significant sources of C. difficile community-acquired infection?. J Appl Microbiol. 2016; 122(3):542-553. DOI: 10.1111/jam.13338. View

Lozupone C, Knight R . UniFrac: a new phylogenetic method for comparing microbial communities. Appl Environ Microbiol. 2005; 71(12):8228-35. PMC: 1317376. DOI: 10.1128/AEM.71.12.8228-8235.2005. View

10.

Manges A, Labbe A, Loo V, Atherton J, Behr M, Masson L . Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridum difficile-associated disease. J Infect Dis. 2010; 202(12):1877-84. DOI: 10.1086/657319. View

11.

Schneider D, Thurmer A, Gollnow K, Lugert R, Gunka K, Gross U . Gut bacterial communities of diarrheic patients with indications of Clostridioides difficile infection. Sci Data. 2017; 4:170152. PMC: 5644368. DOI: 10.1038/sdata.2017.152. View

12.

Xia J, Gao J, Tang W . Nosocomial infection and its molecular mechanisms of antibiotic resistance. Biosci Trends. 2016; 10(1):14-21. DOI: 10.5582/bst.2016.01020. View

13.

Meyer M, Kircher M . Illumina sequencing library preparation for highly multiplexed target capture and sequencing. Cold Spring Harb Protoc. 2010; 2010(6):pdb.prot5448. DOI: 10.1101/pdb.prot5448. View

14.

DeSantis T, Hugenholtz P, Larsen N, Rojas M, Brodie E, Keller K . Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol. 2006; 72(7):5069-72. PMC: 1489311. DOI: 10.1128/AEM.03006-05. View

15.

Monaghan T . New perspectives in Clostridium difficile disease pathogenesis. Infect Dis Clin North Am. 2015; 29(1):1-11. DOI: 10.1016/j.idc.2014.11.007. View

16.

Goudarzi M, Seyedjavadi S, Goudarzi H, Aghdam E, Nazeri S . Clostridium difficile Infection: Epidemiology, Pathogenesis, Risk Factors, and Therapeutic Options. Scientifica (Cairo). 2014; 2014:916826. PMC: 4058799. DOI: 10.1155/2014/916826. View

17.

Peretz A, Tkhawkho L, Pastukh N, Brodsky D, Halevi C, Nitzan O . Correlation between fecal calprotectin levels, disease severity and the hypervirulent ribotype 027 strain in patients with Clostridium difficile infection. BMC Infect Dis. 2016; 16:309. PMC: 4918013. DOI: 10.1186/s12879-016-1618-8. View

18.

Debast S, Vaessen N, Choudry A, Wiegers-Ligtvoet E, van den Berg R, Kuijper E . Successful combat of an outbreak due to Clostridium difficile PCR ribotype 027 and recognition of specific risk factors. Clin Microbiol Infect. 2009; 15(5):427-34. DOI: 10.1111/j.1469-0691.2009.02713.x. View

19.

Antharam V, Li E, Ishmael A, Sharma A, Mai V, Rand K . Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J Clin Microbiol. 2013; 51(9):2884-92. PMC: 3754663. DOI: 10.1128/JCM.00845-13. View

20.

Caporaso J, Kuczynski J, Stombaugh J, Bittinger K, Bushman F, Costello E . QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010; 7(5):335-6. PMC: 3156573. DOI: 10.1038/nmeth.f.303. View